Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999.
Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999. Prefilled syringes will come in 10-mL, 15-mL, and 20-mL sizes. Berlex believes that prefilled syringes will save time and reduce the potential for contamination and needle stick incidents that might occur when Magnevist syringes are filled manually.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.